A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroids).

Trial Profile

A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroids).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2016

At a glance

  • Drugs Laquinimod (Primary) ; Corticosteroids; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 15 Jun 2013 Results presented at the 14th Annual Congress of the European League Against Rheumatism.
    • 12 Jun 2013 Data will be presented during the 2013 European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, according to a Teva Pharmaceutical Industries media release.
    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top